Little Journey Secures £6 Million for Global Expansion
On November 18, 2024, Little Journey, a pioneering healthtech company dedicated to enhancing paediatric care through personalised psychological support, announced a significant achievement in its funding journey. The company has successfully raised £6 million in a Series A funding round, led by the Edinburgh and Leeds-based venture capital firm, Par Equity. This investment round saw additional contributions from notable partners including Mercia Ventures, the Northern Powerhouse Investment Fund, Octopus Ventures, Calm/Storm Ventures, and various angel investors who bring valuable expertise in healthcare and life sciences. This substantial funding will allow Little Journey to scale its operations globally and make critical enhancements to its product offerings.
The funding will primarily target the expansion of Little Journey's operations, particularly within the United States healthcare market.
With a solid foundation of early adopters, the company is poised to broaden its reach and offer transformative support to a greater number of children and families across the globe. In addition to scaling operations, the funds will fuel the development of improved product features, including data collection capabilities and functionalities that allow for greater interoperability. These enhancements aim to enable healthcare organizations to implement data-focused, patient-centric approaches to care, ultimately driving better health outcomes for paediatric patients worldwide. Moreover, the investment will reinforce the robustness and security of Little Journey's infrastructure to facilitate successful global adoption.
Chris Evans, the Co-Founder and CEO of Little Journey, expressed enthusiasm regarding the new funding, highlighting its potential to expand the company's impact in the paediatric healthcare sector. He noted that while various legislation has increased clinical study numbers, there is still a significant gap in specialist paediatric knowledge, resulting in challenges like lower recruitment and adherence rates. With the support of Par Equity and other investors, Little Journey is well-equipped to address these challenges and redefine the execution of paediatric clinical trials, putting families at the forefront of its efforts. Co-Founder and Chief Product Officer, Sophie Copley, also shared her excitement about the future direction of the company's offerings, emphasizing enhancements to data capabilities that would further globalise their services. Little Journey’s commitment to compassionate, personalised care aims to empower families and improve the overall healthcare experience for children around the world.
They've invested in Little Journey
Get to know these Healthtech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 Par Equity | 11 investments investments | 9 contacts contacts | |||
 Mercia | 100 investments investments | 14 contacts contacts | |||
 British Business Bank | 70 investments investments | 7 contacts contacts | |||
 Octopus Ventures | 50 investments investments | 14 contacts contacts | |||
 Calm Storm | 1 investment investment | 3 contacts contacts |
Click here for a full list of 7,526+ startup investors in the UK